CAP ’14 Media Hot Topics

Media are invited to attend CAP ’14 scientific events and education courses, featuring the latest in laboratory medicine today, including molecular pathology, genetic testing, test utilization, clinical informatics, and the pathologist’s role in coordinated care models.

Below is a listing of events and courses open to the media—CAP’14 registration is free for the press. Please contact CAP media for press credentials or to arrange an interview with a faculty member.

Sunday, September 7, 2014

SPECIAL SCIENTIFIC PLENARY: P1400 Molecular Medicine—Can We Afford It?
Sunday, September 7
8:00-9:15 AM
Co-Sponsored by the Association for Molecular Pathology
How does genomic/molecular testing fit into traditional and new health economic models? Pathologists must consider the economic implications of the rapidly increasing use of molecular medicine on health care systems, as well as the individual laboratory and patient.

Hear from three national thought leaders on this critical topic. Debra G. B. Leonard, MD, PhD, FCAP, a pathologist at the University of Vermont, will speak to the technical and business issues of molecular testing. David O. Meltzer, MD, PhD, a health economist at the University of Chicago, will focus on measuring the economic impacts of genomic medicine. Adam C. Berger, PhD, director of the prestigious Institute of Medicine’s Roundtable on Translating Genomic-Based Research for Health, will moderate the session.

Faculty: Adam Berger, PhD, Institute of Medicine’s Roundtable on Translating Genomic-Based Research for Health
Debra G.B. Leonard, MD, PhD, FCAP, University of Vermont
David O. Meltzer, MD, PhD, University of Chicago

Advances in Molecular Testing for Cancers of the Stomach and the Esophagus
S1306 HER2 Testing in Gastric and Gastroesophageal Junction Cancers: A New Therapeutic Target and Diagnostic Challenge
Sunday, September 7
9:30–11:30 AM
The recent approval trastuzumab for advanced gastric/gastroesophageal junction (GEJ) adenocarcinoma offers a much-needed therapeutic option. Accurate HER2 testing is critical to determine which patients are eligible for this life-prolonging therapy. The presenters will provide results of the first clinical trial to demonstrate a benefit of the targeted therapy and will review interpretive guidelines for HER2 assessment.

Faculty: David Hicks, MD, FCAP, University of Rochester Medical Center
Christa Whitney-Miller, University of Rochester Medical Center
S1405 CAP-ADASP Interpretive Diagnostic Error Reduction Through Targeted Case Reviews
Sunday, September 7
9:30-11:30 AM
The CAP and the Association Directors of Anatomic and Surgical Pathology (ADASP) convened a panel of experts to investigate the role of second-pathologist review in preventing diagnostics interpretive errors. A systemic literature review was performed to answer the question: Does targeted review of surgical pathology or cytopathology cases reduce the error rate before case sign-out and if so, what are the best methods? Faculty will discuss implementation of the final recommendations in different practice settings.

Faculty: Raouf Nakhleh, MD, FCAP, Mayo Clinic

S1403 Implementing Whole Slide Imaging for Clinical Use: What to Do and What to Avoid
Sunday, September 7
9:30-11:30 AM
There is a growing interest in using whole slide imaging (WSI) systems for a variety of clinical purposes in pathology. Specific applications include primary and frozen section diagnosis, pathologist-to-pathologist consultations, and multidisciplinary tumor conferences. This course provides an opportunity for those considering the use of WSI for clinical applications to interact with early adopters, allowing them to develop a practical implementation strategy. Faculty members are also available to discuss evidence-based guideline on validation of WSI.

Faculty: Andrew Evans, MD, PhD, University of Toronto
Walter Henricks, MD, FCAP, Cleveland Clinic Foundation
Liron Pantanowitz, MD, FCAP, University of Pittsburgh Medical Center
Mohamed Salama, MD, ARUP Laboratories, Inc.

S1404 Clinical Next-Generation Sequencing for Cancer: How We Did It, What We Learned
Sunday, September 7
9:30-11:30 AM
Next-generation sequencing (NGS) of DNA is radically transforming pathology. In particular, it now provides unique insights into cancer in the clinical setting that allow us to supply better and more complete information for the care of our patients. Faculty will present the experience of a large cancer center with clinical implementation of NGS using multiple gene panels and performance platforms for both hematopoietic and solid malignancies.

Faculty: Michael Davies, MD, PhD, University of Texas MD Anderson Cancer Center
Alexander Lazar, MD, PhD, FCAP, University of Texas MD Anderson Cancer Center
Keyur Patel, MD, PhD, FCAP, University of Texas MD Anderson Cancer Center
Mark Routbort, MD, PhD, FCAP, University of Texas MD Anderson Cancer Center

H1315 Genomic Pathology 101: Practical Information for the Practicing Pathologist
Sunday, September 7, 2014
2:00-5:30 PM
As diagnosticians, pathologists must understand genomic testing. The cost of a whole exome sequence is approaching $1,000, and next-generation sequencing (NGS) has already led to personalized chemotherapy for cancer patients, which is being rapidly incorporated into patient care. Through lecture and interactive approaches, pathologists in academia and private practice will learn critical information regarding genomic medicine by attending this session. The presenters will provide key basics in molecular pathology followed by information on using NGS methodology, evaluating clinical utility of genomic tests in pathology, and communicating results to other clinicians. Members of a national genomics education committee who are experts in molecular pathology, medical education, and genetic counseling have developed the session.

Faculty: Richard L. Haspel, MD, PhD, FCAP, Beth Israel Deaconess Medical Center
Debra G.B. Leonard, MD, PhD, FCAP, University of Vermont
John D. Pfeifer, MD, PhD, FCAP, Washington University School of Medicine
The Many Facets for Diagnostic Testing for Hodgkin Lymphomas

**S13212 Hodgkin Lymphomas: What Every Practicing Pathologist Needs to Know**
Sunday, September 7
2:00-4:00 PM

Hodgkin lymphoma has remained a mystery for generations. In 2014, the National Cancer Institute estimates more than 9,000 Americans will be diagnosed with this cancer of the immune system. This course provides a historic perspective on Hodgkin lymphoma, and then describes the range of morphologic and immunophenotypic features displayed in individual cases, including patterns of expression of novel transcription factors, emphasizing features that permit distinction from Hodgkin lymphoma from both malignant and benign pathologic mimickers.

**Faculty:** Patrick Treseler, MD, PhD, FCAP, University of California San Francisco

The Role of the Pathologist in Test Utilization

**H1216 Establishing a Laboratory Test Utilization Management Program: Organizational Structure, Informatics, and the Central Role of the Pathologist**
Sunday, September 7
2:00-5:00 PM

Current and future reimbursement models will increasingly focus on controlling unnecessary utilization while improving the overall quality of care. Many studies have described individual initiatives to control the utilization of one or a few tests. However, there is little published experience with establishing an ongoing utilization management program.

**Faculty:** Jason Baron, MD, FCAP, Massachusetts General Hospital
John Branda, MD, Massachusetts General Hospital
Kent Lewandrowski, MD, FCAP, Massachusetts General Hospital

Advances in Molecular Diagnostic Testing of Breast Cancer

**M1221 Treatment Implication of ER-Positive and HER2-Positive Breast Cancer—The Critical Role of Pathologists**
Sunday, September 7
4:30-5:30 PM

Breast cancer is a disease with significant clinical diversity, necessitating an individual approach to its management. Of central importance to this decision-making is the evaluation of the predictive markers ER, PgR, and HER2 that are routinely utilized to help define treatment. Given the role of these predictive markers in determining therapy, assay results must be as precise as possible. Using cases of ER and HER2 testing as examples, the presenters will illustrate important issues encountered in correct interpretation of ER and HER2.

**Faculty:** David Hicks, MD, FCAP, University of Rochester Medical Center
Ping Tang, MD, PhD, FCAP, University of Rochester Medical Center

Monday, September 8, 2014

Surveying the Latest in Diagnosing Hepatitis

**H1331 Liver Pathology in the Changing World of Endocrine, Metabolic, Infective, and Immunologic Disorders**
Monday, September 8
8:00-11:30 AM

Diabetes and metabolic syndrome pose new challenges while increasingly successful antiviral therapy promises to lessen the disease burden from viral hepatitis—a disease affecting 4.4 million Americans. Viral hepatitis is the leading cause of liver cancer and the most common reason for liver transplantation. Pathologists are asked for important information, some related to new drugs, others to primary immunologic aberrations or secondary to metabolic, endocrine, drug reaction, or infective causes.

**Faculty:** Oyedele Adeyi, MBBS, FCAP, University of Health Network
Sandra Fischer, MD, University of Health Network
H1328 Optimizing Laboratory Test Utilization: The Pathologist’s Expanding Role
Monday, September 8, 2014
8:00-11:30 AM
In this era of decreasing reimbursement, accountable care payment models, and explosive growth of laboratory technologies, pathologists and laboratories face increasing internal and external pressures to decrease the cost of laboratory testing. Pathologists must fill the critical leadership role necessary to direct cost-effective and appropriate laboratory testing while continuing to deliver high-quality care to the patient. The presenters will share real-life examples of successful approaches and will provide ample opportunity for audience discussion and questions.

Faculty: Curt A. Hanson, MD, FCAP, Mayo Clinic
Paul J. Kurtin, MD, FCAP, Mayo Clinic
Bobbi S. Pritt, MD, MSc, FCAP, Mayo Clinic

H1427 The Great Mimickers in Hematopathology: Malignancies That Appear Benign and Benign Lesions That Appear Malignant
Monday, September 8, 2014
8:00-11:30 AM
The faculty will present key distinguishing clinicopathologic features, newer immunohistochemical markers, and applicable molecular assays useful in the diagnostic work-up of challenging lymphoid lesions. Strategies for the cost-effective use of ancillary testing to confirm diagnoses will be discussed.

Faculty: Parul Bhargava, MBBS, FCAP, Beth Israel Deaconess Medical Center
Sherrie L. Perkins, MD, PhD, FCAP, ARUP Laboratories

S1438 Pathologist Value: Making a Difference in ACOs
Monday, September 8, 2014
2:00-4:00 PM
This course is presented by the CAP ACO Network and features representatives of the network from a variety of practice settings where accountable care organizations (ACOs) and other coordinated care models are or will soon be in operation. With more than 500 ACOs currently in operation in the US, members of the CAP ACO Network will share best practices and lessons learned based on their experiences. Faculty will also explore the challenges and opportunities pathologists have to demonstrate value, exercise leadership, and influence patient and population management within a team-based model.

Faculty: James M. Crawford, MD, PhD, FCAP, North Shore Hospital
Donald S. Karcher, MD, FCAP (Moderator), George Washington Medical Center
Debra G.B. Leonard, MD, PhD, FCAP, The University of Vermont
Patrick A. Twomey, MD, FCAP, St. Mary’s / Duluth Clinic

S1342 Empowering Pathology in the Electronic Health Record Era
Monday, September 8, 2014
2:00-4:00 PM
Electronic health records (EHRs) are transforming medical practice and information management. The shift to the EHRs as the primary electronic data system in a health system poses challenges, risks, and opportunities for pathology and laboratory medicine. Laboratory data are among the most actionable data available to a hospital and health care organization. Pathologist and laboratory expertise is required but often lacking in EHR implementations. In this course, pathologists will learn how to address gaps in laboratory information management in the EHR stemming from lack of laboratory expertise and to empower themselves and their laboratories in the era of the EHR.

Faculty: Ramy Arnaout, MD, PhD, FCAP, Beth Israel Deaconess Medical Center
Raj C. Dash, MD, FCAP, Duke University Hospital and Health Systems
Walter H. Henricks, MD, FCAP, Cleveland Clinic Foundation
S1341 ASCO/CAP HER2 Guideline Revision: What’s New?
Monday, September 8, 2014
2:00-4:00 PM
As one of the members of the steering committee of the 2013 ASCO/CAP HER2 update, faculty will compare and contrast the elements from 2007 and 2013 Guideline Recommendations and explain the significance of the changes to patient care.

Faculty: David G. Hicks, MD, FCAP, University of Rochester Medical Center

S1443 Customizing the Laboratory Information System to Improve Patient Safety and Workflow in the Pathology Laboratory
Monday, September 8, 2014
2:00-4:00 PM
Pathology informatics has become critical to help pathology laboratories meet current and future challenges. Some of these challenges include providing laboratories with tools such as bar coding and tracking, synoptic reporting, and automated QA assessment tools. The speakers will demonstrate key aspects of the laboratory information systems and how tools such as bar coding and tracking, synoptic reporting, and prospective peer review at sign-out within the laboratory information system are enablers of improved pathology practice and workflow. This course is co-sponsored by the Association for Pathology Informatics.

Faculty: Liron Pantanowitz, MD, FCAP, University of Pittsburgh Medical Center
Anil V. Parwani, MD, PhD, FCAP, University of Pittsburgh Medical Center

S1445 Prostate Pathology: Current Concepts and Controversies 2014
Monday, September 8, 2014
2:00-4:00 PM
2.0 CME Credits
This course will emphasize practical current diagnostic criteria and terminology for prostate cancer, highlighting mimics that pose potential pitfalls, as well as adjunct biomarkers and their utility. Faculty will present information about current concepts and controversial topics in an objective and empirical format.

Faculty: David G. Bostwick, MD, MBA, FCAP, Bostwick Laboratories, Inc.
Kenneth A. Iczkowski, MD, FCAP, Urology Specialists of America

Tuesday, September 9, 2014

Emerging Molecular Approaches to Diagnosing Leukemia and Other Bone Marrow Diseases
1450 Back to the Future: Molecular Testing of Myeloproliferative Neoplasms in 2014
Tuesday, September 9, 2014
8:00-9:00 AM
Hear a timely review of the application of molecular testing to the diagnosis of myeloproliferative neoplasms (MPNs)—diseases affecting bone marrow, such as leukemia. Using a case-based format, faculty will present a contemporary approach to the integration of morphologic and genetic findings for the workup of MPNs and will discuss optimal strategies for initial testing and follow-up, including choice of methodology (ie, FISH versus karyotype versus PCR, etc). The presenter will also introduce several recently identified recurrent mutations that promise to revolutionize this area of clinical practice. Finally, the impact of exciting new analytic approaches in the laboratory will be discussed. Faculty will review which tests are necessary, and when, how, and why to use them.

Faculty: David R. Czuchlewski, MD, FCAP, University of New Mexico Health Sciences Center
Microscopy Without the Microscope: New Ways to Guide Clinical Decision Making

Tuesday, September 9, 2014
4:00-5:00 PM

Learn about new optical methods that have been developed that may upend conventional ways of examining tissues. These approaches can generate cellular images, even from inside the patient, and may supplement or replace conventional microscopy techniques. Some, like optical coherence tomography and confocal endomicroscopy, are in clinical practice. Others, such as multiphoton microscopy, are emerging but promising, and may achieve clinical traction. The cost and complexity of technologies vary, but there will be major impacts on clinical workflow and biopsy numbers. Improved surgical guidance and accelerated patient care would be among the benefits.

Faculty: Richard M. Levenson, MD, FCAP, University of California, Davis Medical Center

Live or Let Die: Clinical Informatics as a Transformative Discipline for Pathologists in the New Era of Value-Based Health Care

Tuesday, September 9, 2014
1:30-5:00 PM

Accountable care organizations, bundled payments, and value-based purchasing are emerging health care fiscal reforms initiated by the Affordable Care Act. While pathology and clinical laboratory services account for less than 5% of health plan costs, their effect on clinical care is far greater. Clinical informatics will be crucial for making data-driven decisions in these new health care models. By taking ownership of clinical informatics within your organization, attendees will be able to more effectively demonstrate their professional value and be better prepared to drive improvements in clinical quality and cost management.

Faculty: Philip C. Chen, MD, PhD, FCAP, University of Miami
James M. Crawford, MD, PhD, FCAP, North Shore University Hospital
Franklin R. Elevitch, MD, FCAP, Health Care Engineering

The Evolution of GI Histopathology

Tuesday, September 9, 2014
5:30-6:30 PM

Can the evolution of GI pathology build on and predict its role in the future? Join us as Robert H. Riddell, MD, FRCPat, FRCPC, a world-renowned gastrointestinal pathologist, author, and speaker, shares his professional experience and perspective for fostering growth of the discipline in the modern era. Dr. Riddell is the section head of gastrointestinal pathology at Mt. Sinai Hospital in Toronto and is a professor of Laboratory Medicine and Pathobiology at the University of Toronto.

Faculty: Robert H. Riddell, MD, FCCPath, FRCPC, University of Toronto

Laboratory Director Boot Camp—What, When, Why, and How to Validate New Tests and Meet Regulatory Requirements

Wednesday, September 10, 2014
8:00-11:30 AM

Laboratory Director Boot Camp will provide attendees with the knowledge and skills to bring on new clinical laboratory tests in clinical chemistry, hematopathology, coagulation, and molecular diagnostics. The faculty will provide a general overview of the CLIA and CAP regulatory requirements for the implementation of new tests, including conducting test validation, defining the analytical measurement range (as appropriate for quantitative assays), establishing reference ranges, and meeting the requirements for ongoing monitoring of test performance including participation in proficiency testing.

Faculty: Keri J. Donaldson, MD, FCAP, Penn State Milton S. Hershey Medical Center
Wieslaw B. Furmaga, MD, FCAP, University of Texas Health Science Center
**H1477 Patient Blood Management Program—What You Need to Know**  
*Wednesday, September 10, 2014  
8:00-11:30 AM*  
Learn how to start and/or enhance a Patient Blood Management Program. Faculty will focus on reducing blood usage by defining guidelines for use of red blood cells, platelets and plasma and use of order sets. Guidelines will be provided for anemia management before and during surgery, aspects of blood transfusion and changes in blood during storage, as well as the avoidance of hospital-acquired anemia by blood volume reduction and test utilization.  

*Faculty:*  
Jerome L. Gottschall, MD, FCAP, Blood Center of Wisconsin  
Evelyn L. Lockhart, MD, FCAP, Duke University Medical Center  
Lowell L. Tilzer, MD, PhD, FCAP, University of Kansas Medical Center

**H1381 Gastrointestinal Pathology: Bridging the Gap Between Molecular and Practical**  
*Wednesday, September 10, 2014  
8:00-11:30 AM*  
Targeted to practicing surgical pathologists and pathology residents, this session addresses problem areas in gastrointestinal pathology where immunohistochemical and molecular information impacts everyday practice. Faculty will discuss a practical approach to molecular testing for colorectal carcinoma; the latest recommendations for diagnosis, testing, management, and surveillance of serrated lesions of the gut, polyps, and polyposis syndromes; diagnosis, surveillance, and management of Barrett esophagus; and the latest guidelines for diagnosis of celiac sprue, including the classification of refractory sprue. Furthermore, you will learn a practical approach to the differential diagnosis and molecular testing of stromal lesions of the gut.  

*Faculty:*  
Robert E. Petras, MD, FCAP, AmeriPath, Cleveland

**S1282 Next-Generation Sequencing for Inherited Disorders**  
*Wednesday, September 10, 2014  
9:30-11:30 AM*  
The diagnostic application of next-generation sequencing (NGS) of inherited disorders in the clinical setting offers new challenges and practice opportunities for pathologists. Faculty will update participants on NGS principles and processes and describe clinical scenarios and examples in which NGS based multigene panel and exome sequencing are being applied. They will highlight the essential role of bioinformatics in NGS data analysis and present approaches to exome-scale data analysis for causal gene identification in patients with suspected genetic disorders.  

*Faculty:*  
Wayne W. Grody, MD, PhD, FCAP, UCLA Center for Health Sciences  
Karl V. Voelkerding, MD, FCAP, ARUP Laboratories

**S1390 The Metabolic Syndrome**  
*Wednesday, September 10, 2014  
1:30-3:30 PM*  
Although the metabolic syndrome is becoming better known in the lay press and in professional journals, the extent to which it affects multiple organ systems and biochemical processes may not be well appreciated. Because of its pervasiveness, pathologists will, nevertheless, deal with the metabolic syndrome in all practice situations. Laboratory testing is key to the diagnosis and management of the metabolic syndrome and its consequences. The clinical care of patients can be improved by screening for and treating diabetes, dyslipidemia, hyperuricemia, hepatic dysfunction, and renal dysfunction. In this session, you will learn how to diagnose the metabolic syndrome, explain its pathogenesis, and order and interpret appropriate laboratory testing relevant to the metabolic syndrome. This course is cosponsored by American Association for Clinical Chemistry  

*Faculty:*  
William E. Winter, MD, FCAP, University of Florida
S1391 Beyond Single Gene Analysis: Paving the Way to Comprehensive Tumor Genomic Profiling
Wednesday, September 10, 2014
1:30-3:30 PM
Faculty members will focus on the design and implementation of multitargeted molecular testing in clinical practice, with consideration of both sequential single-gene testing algorithms and parallel multiplexed assays. This course is ideal for practitioners within the field of cancer pathology, with an emphasis on molecular diagnostics. Presenters will share their experiences with targeted genotyping assays in lung cancer, colon cancer, thyroid cancer, and melanoma, as well as with the PROFILE™ initiative, an effort to provide multiplexed genetic analysis of all cancer samples. Additionally, faculty will offer insight into the keys to success and potential pitfalls to avoid in establishing a broad tumor-genotyping platform in an academic center. This course is cosponsored by the Association for Molecular Pathology.

Faculty: Neal I. Lindeman, MD, FCAP, Brigham & Women’s Hospital
Lynette M. Sholl, MD, Brigham & Women’s Hospital